Tesaro Inc. (TSRO) Price Target Raised to $128.00
Tesaro Inc. (NASDAQ:TSRO) had its price target boosted by stock analysts at RBC Capital Markets to $128.00 in a note issued to investors on Monday. RBC Capital Markets’ target price would suggest a potential upside of 28.95% from the company’s current price.
Several other analysts have also issued reports on TSRO. Zacks Investment Research lowered shares of Tesaro from a “hold” rating to a “sell” rating in a research report on Wednesday, June 15th. FBR & Co lifted their target price on shares of Tesaro from $65.00 to $93.00 and gave the company an “outperform” rating in a research report on Wednesday, June 29th. Jefferies Group lowered shares of Tesaro from a “buy” rating to a “hold” rating and lifted their target price for the company from $53.00 to $75.00 in a research report on Thursday, June 30th. They noted that the move was a valuation call. Leerink Swann lifted their target price on shares of Tesaro from $65.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, June 30th. Finally, Mizuho reiterated an “outperform” rating and issued a $67.00 target price on shares of Tesaro in a research report on Thursday, June 30th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $102.69.
Shares of Tesaro (NASDAQ:TSRO) opened at 99.26 on Monday. Tesaro has a 52-week low of $29.51 and a 52-week high of $110.48. The company has a 50-day moving average of $96.42 and a 200-day moving average of $68.96. The stock’s market capitalization is $5.10 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/tesaro-inc-tsro-price-target-raised-to-128-00.html
Tesaro (NASDAQ:TSRO) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The business had revenue of $36.60 million for the quarter, compared to analyst estimates of $4.98 million. During the same quarter last year, the business earned ($1.51) earnings per share. Equities research analysts anticipate that Tesaro will post ($7.36) EPS for the current year.
In other Tesaro news, VP Edward C. English sold 7,000 shares of the business’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $88.54, for a total value of $619,780.00. Following the transaction, the vice president now directly owns 3,500 shares in the company, valued at approximately $309,890. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total transaction of $44,112.96. Following the completion of the sale, the senior vice president now directly owns 1,250 shares in the company, valued at $135,150. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. bought a new stake in Tesaro during the second quarter worth about $228,000. Amalgamated Bank bought a new stake in Tesaro during the second quarter worth about $260,000. Quantitative Systematic Strategies LLC bought a new stake in Tesaro during the second quarter worth about $240,000. Bluestein R H & Co. bought a new stake in Tesaro during the second quarter worth about $252,000. Finally, Neuberger Berman Group LLC bought a new stake in Tesaro during the second quarter worth about $256,000. 88.81% of the stock is currently owned by institutional investors and hedge funds.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.